Europe and Northern America vs Sri Lanka: Percentage of bloodstream infection due to Escherichia coli resistant
Europe and Northern America
11.6%
in 2022
Sri Lanka
58.8%
in 2022
Europe and Northern America rank
15th
Sri Lanka rank
12th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- Europe and Northern America
- Sri Lanka
How they compare
Sri Lanka currently reports 58.8% against 11.6% in Europe and Northern America, a difference of 47.2%.
That makes Sri Lanka's figure about 5.1 times Europe and Northern America's.
Across all 5 years both countries report, Sri Lanka has been ahead every year.
Europe and Northern America ranks 15th and Sri Lanka ranks 12th of 16 groups.
Sri Lanka has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Europe and Northern America | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 25.2% | 65.3% | 40.1% | Sri Lanka |
| 2020s | 11.5% | 59.2% | 47.8% | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, Europe and Northern America or Sri Lanka?
- Sri Lanka, at 58.8% against 11.6% in Europe and Northern America as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between Europe and Northern America and Sri Lanka?
- 47.2%, with Sri Lanka ahead.
- How many years of comparable data are there for Europe and Northern America and Sri Lanka?
- 5 years are reported by both, from 2018 to 2022.
- How do Europe and Northern America and Sri Lanka rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- Europe and Northern America ranks 15th and Sri Lanka ranks 12th of 16 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.